Skip to content


Dr Errol De Souza PhD
Executive Chairman

Dr De Souza is a leader in the development of therapeutics for the treatment of central nervous system disorders. He has over 35 years’ experience as an executive in the biopharmaceutical industry. He has served as President and CEO of public (Biodel Inc., Synaptic Pharmaceutical Corp), and private (Archemix Corp., Neuropore Therapies Inc) Companies. Dr De Souza founded Neurocrine Biosciences Inc. taking it Public (IPO). Dr De Souza has raised several hundred million dollars in capital in private and public sectors and sold companies (Synaptic sale to Lundbeck). Over his career, he has served as SVP at Aventis, co-founder and EVP of R&D at Neurocrine and Head of CNS at DuPont Merck. Dr De Souza has served on multiple public and Private boards, National Institutes of Health Committees and currently serves as a Board Director of Catalyst Biosciences, Inc and Royalty Pharma plc.

Dr Errol De Souza – Executive Chairman

Mr Adrian Hinton BEc, FCA

Chief Financial Officer (Acting)

Mr Hinton has had a long career with Deloitte (Adelaide) of over 43 years, retiring 1 July 2018 as Principle in the Audit and Assurance Group. He was responsible for managing the audit services to various Adelaide based public and private companies. His experience has given Mr Hinton a broad-based knowledge of contemporary accounting and audit issues inclusive of experience in working with a wide range of clients in different industries, from listed entities, private corporations to major subsidiaries of multinational listed companies, covering consumer, agriculture, retail, manufacturing, automotive, biopharmaceutical and resources sectors. Mr Hinton also has experience in preparing due diligence reviews, investigative accounting reports and the review of profit forecasts. Mr Hinton’s experience is currently benefited by being on the Boards of The Multiple Sclerosis Society of South Australia and Northern Territory, Carers Association of SA Inc, Australia PNG Alliance Group Pty Ltd and the Audit and Risk Committee of the University of South Australia. Mr Hinton also volunteers his time and skill set to aiding community groups both locally and internationally.

Mr Adrian Hinton – Chief Financial Officer (Acting)

Ms Liz Doolin MSc

Vice President Clinical Development

Ms Doolin has over 25 years international experience in drug discovery, clinical and life sciences research. She joined Bionomics Limited in 2008 to lead the early clinical development program for BNC210, a small molecule with therapeutic potential for anxiety disorders, and trauma and stressor-related disorders including PTSD. Ms Doolin currently leads Bionomics’ clinical programs across central nervous system disorders and oncology, including three novel investigational drugs in Phase 1 and 2 clinical development. In addition to her extensive clinical research experience in Australia, Ms Doolin has a strong immunology and biotechnology research background, as well as biopharmaceutical development and GMP manufacturing experience, gained in New Zealand and the UK.

Ms Liz Doolin – Vice President of Clinical Development

Mr Connor Bernstein MSc
Vice President of Strategy & Corporate Development

Mr Bernstein has 10 years of experience in Life Sciences Investment Banking in strategic advisory, M&A, and equity and debt financings with broad execution expertise. Mr Bernstein leverages his biopharma domain industry knowledge with Apeiron Investment Group evaluating and assisting biotech companies in finance, strategy, corporate development and investor relations. His prior Healthcare Investment Banking roles include RBC Capital Markets, Perella Weinberg Partners, Guggenheim Securities and Piper Jaffray.

Mr Connor Bernstein Vice President Strategy & Corporate Development

Mr Connor Bernstein – Vice President Strategy & Corporate Development